Literature DB >> 7478120

Can immunosuppressive drugs slow the progression of IgA nephropathy?

D Goumenos1, M Ahuja, J R Shortland, C B Brown.   

Abstract

The role of immunosuppressive drugs in the treatment of IgA nephropathy (IgAN) remains controversial. The effect of treatment with prednisolone and azathioprine on the clinical course of patients with IgA nephropathy is described in this retrospective study. One hundred and fourteen patients, 66 treated (age 13-77 years) and 48 untreated (age 15-64 years), were evaluated. The two groups of patients differed significantly with respect to heavier proteinuria (median 3.6 g/day, range 0.2-18 g/day), lower serum albumin level (< 40 g/l) and more severe renal histopathological involvement in the treated group (P < 0.01). Oral prednisolone 40 mg/day and azathioprine 2 mg/kg BW/day was commenced initially and after gradual tapering was continued at low dose (5 mg/day) for a median duration of 24 months (range 12-98). The median duration of follow-up was 46 months (range 12-180). The clinical course was defined as progressive or non-progressive on the basis of serial serum creatinine (Scr). Of the patients who presented with renal impairment (Scr > 110 mumol/l), a non-progressive course was observed in 79.5% patients of the treated group (n = 39), while only in 36% of the untreated group (n = 22), the difference was statistically significant (P < 0.001). Slopes of reciprocal of Scr versus time were also calculated by linear regression analysis to represent the trend of renal function for patients who had had 3 or more years follow-up (n = 101). An analysis of variance of these trends in patients with renal impairment at presentation (n = 51) showed significant recovery of renal function in the treated group (n = 33) and a decline of renal function in the untreated group (n = 18, P = 0.004). There was no significant effect of the treatment on proteinuria. The histopathological features that favoured response to the treatment were mesangial proliferation, capsular adhesions and interstitial infiltration on light-microscopy, C3 and fibrin deposits on immunofluorescence (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478120

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Long-term results of a randomized controlled trial in childhood IgA nephropathy.

Authors:  Koichi Kamei; Koichi Nakanishi; Shuichi Ito; Mari Saito; Mayumi Sako; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

Review 2.  Recognition and management of IgA nephropathy.

Authors:  L S Ibels; A Z Gyory; R J Caterson; C A Pollock; J F Mahony; D A Waugh; S Coulshed
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 3.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

4.  Steroids and azathioprine in the treatment of IgA nephropathy.

Authors:  Maria Stangou; Domniki Ekonomidou; Panagiotis Giamalis; Helen Liakou; Apostolis Tsiantoulas; Afroditi Pantzaki; Aikaterini Papagianni; George Efstratiadis; Efstathios Alexopoulos; Dimitrios Memmos
Journal:  Clin Exp Nephrol       Date:  2011-02-08       Impact factor: 2.801

5.  Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.

Authors:  Claudio Pozzi; Simeone Andrulli; Antonello Pani; Patrizia Scaini; Lucia Del Vecchio; Giambattista Fogazzi; Bruno Vogt; Vincenzo De Cristofaro; Landino Allegri; Lino Cirami; Aldo Deni Procaccini; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2010-07-15       Impact factor: 10.121

6.  In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression.

Authors:  Claudio Bazzi; Virginia Rizza; Sara Raimondi; Daniela Casellato; Pietro Napodano; Giuseppe D'Amico
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

7.  Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria.

Authors:  Ozlem Harmankaya; Yahya Oztürk; Taner Baştürk; Aydoğan Obek; Işin Kiliçarslan
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

8.  Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?

Authors:  Hernán Trimarchi; Mariano Forrester; Fernando Lombi; Vanesa Pomeranz; Romina Iriarte; María Soledad Raña; Pablo Young
Journal:  Int J Nephrol       Date:  2012-05-21

9.  Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone.

Authors:  Y C Hwang; T W Lee; M J Kim; M H Yang; C G Ihm
Journal:  Korean J Intern Med       Date:  2001-06       Impact factor: 2.884

10.  Corticosteroids in patients with IgA nephropathy and severe chronic renal damage.

Authors:  Claudio Pozzi; Francesca Ferrario; Bianca Visciano; Lucia Del Vecchio
Journal:  Case Rep Nephrol       Date:  2012-10-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.